Mon, Oct 20, 2014, 2:17 PM EDT - U.S. Markets close in 1 hr 43 mins


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • bargainrents bargainrents Dec 8, 2013 11:10 AM Flag

    Gene therapy scores big wins against blood cancers

    "It's really exciting," said Dr. Janis Abkowitz, blood diseases chief at the University of Washington in Seattle and president of the American Society of Hematology. "You can take a cell that belongs to a patient and engineer it to be an attack cell. CAN THIS COMPETE WITH SGEN?

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • SGMO?

    • This could be the future of cancer therapy. It's a very exciting field but keep in mind that the first gene therapy trials led to cancer in immunocompromised patients. It's path to success has many unknowns and it would be years before it can compete with SGEN if at all.

      Sentiment: Hold

      • 2 Replies to darwins_frog
      • just saw CTL019 extraordinary results highlighted on NBC nightly news. Like I said, it is the real deal and the reason for today's sell off. After reading the story Sunday I made the decision to sell at the open today. I think it is a game changer and will quickly surpass ADC's in the treatment of blood cancers.
        I'm glad I followed my gut and avoided today's pain. Posted here right after the sell. I'm thinking that this is it for me. A ten year run....This has been my favorite stock because of the excellent work.
        Good Luck to all

      • Norvartis's CTl019 results presented at ASH blows everything away. Who Knew. It's the real deal.

        "In a study evaluating CTL019 for the treatment of children and adults with relapsed/refractory ALL (abstract #67), pediatric patients (n=22) received a targeted T cell dose range of 107 to 108 cells/kg with a transduction efficiency (TE) of 11-45% and adult patients (n=5) received a target dose of 5x109 total cells split over three days with a TE of 6-31%. The study found that 19 of 22 pediatric patients with ALL (86%) experienced complete remissions and all five of the first adult ALL patients treated have thus far experienced complete remissions. There were no infusional toxicities greater than Grade 2, although five patients developed fevers within 24 hours of infusion and did not receive planned subsequent infusions of CTL019 cells[1]."

    • I think this new therapy is in phase I, but looks very ineresting

    • I was wondering the same thing when I saw that item. But, I would think any new 'science' could take years to get through the FDA. It does address the same cancers SGEN is working on.

35.448+0.798(+2.30%)2:17 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.